Linzagolix CAS 935283-04-8

Khoom Qhia:

Khoom npe: linzagolix CAS TSIS: 935283-04-8

Txhais:

5-Carboxy-3- [2-fluoro-5- (2,3-difluoro-6-methoxybenzyloxy) -4-methoxyphenyl] thieno [3,4-d] pyrimidine-2,4 (1H, 3H) -dione;

Tshuaj& Cov Khoom Uas Lub Cev:

Pom: Cov hmoov pob

Ntsuas: ≥98.0%

Qhov ceev: 1.6 ± 0.1 g / cm3

Kev Cia Cia: Qhuav, tsaus thiab nyob rau hauv 0 - 4 ℃ rau lub sij hawm luv luv (hnub mus rau lub lis piam) lossis -20 ℃ rau lub sijhawm ntev (hli txog xyoo).

Solubility: Soluble hauv DMSO

Qhov ncauj ntawm qhov ncauj ua rau lub cev gonadotropin-tso cov tshuaj hormones (GnRH lossis LHRH) receptor antagonist, nrog rau cov tshuaj hormone ntau lawm inhibitory kev ua si. Thaum tswj hwm qhov ncauj ntawm linzagolix, tus neeg sawv cev no sib tw nrog GnRH rau cov kab mob receptor binding thiab inhibits GnRH receptor teeb meem hauv lub caj pas pituitary caj pas, yog li inhibiting qhov tso pa tawm thiab tso tawm luteinizing hormone (LH) thiab follicle stimulating hormone (FSH). Hauv cov txiv neej, qhov inhibition ntawm LH zais cia txwv tsis pub tso tawm testosterone. Raws li qhov tshwm sim, qhov no tuaj yeem txo cov tsos mob cuam tshuam nrog kev tiv thaiv kab mob los tiv thaiv kev tiv thaiv kev tiv thaiv kab mob xws li kev tiv thaiv qog nqaij hlav prostate. Rau cov poj niam, qhov no tiv thaiv kev tsim cov tshuaj estrogen los ntawm lub zes qe menyuam thiab tuaj yeem txo cov tsos mob los ntawm kev sib deev-tso zis ntau yam kabmob, xws li mob cuam tshuam nrog endometriosis, ntshav los ntshav hnyav los yog uterine fibroids.

Yog tias koj txaus siab rau peb cov khoom lossis muaj lus nug, thov koj xav tiv tauj peb!

Cov khoom lag luam hauv qab patent yog muab rau R& D lub hom phiaj nkaus xwb. Txawm li cas los xij, lub luag haujlwm kawg tau txiav txim siab nrog cov neeg yuav khoom.

Cim npe nrov: linzagolix cas 935283-04-8, tuam ntxhab, lwm tus neeg, Hoobkas, yuav, hauv Tshuag

• Tug: Pralsetinib CAS 2097132-94-8
• Tom ntej: Ripretinib CAS 1442472-39-0